This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Assertio (ASRT) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
On Assertio Therapeutics' (ASRT) Q1 earnings call, investors will likely focus on the sales performance of its rheumatology, pain and inflammation medicines.
Investors Heavily Search Assertio Holdings, Inc. (ASRT): Here is What You Need to Know
by Zacks Equity Research
Assertio (ASRT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Assertio (ASRT) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Assertio (ASRT) closed the most recent trading day at $6.01, moving +1.01% from the previous trading session.
Assertio (ASRT) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Assertio (ASRT) closed at $6.30, marking a +0.64% move from the previous day.
Here is What to Know Beyond Why Assertio Holdings, Inc. (ASRT) is a Trending Stock
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Assertio (ASRT). This makes it worthwhile to examine what the stock has in store.
Assertio (ASRT) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Assertio (ASRT) closed at $5.78 in the latest trading session, marking a -0.86% move from the prior day.
Is Trending Stock Assertio Holdings, Inc. (ASRT) a Buy Now?
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Assertio (ASRT). This makes it worthwhile to examine what the stock has in store.
Assertio (ASRT) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Assertio (ASRT) delivered earnings and revenue surprises of 482.61% and 1.58%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Marinus Pharmaceuticals (MRNS) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Marinus Pharmaceuticals (MRNS) delivered earnings and revenue surprises of 16.48% and 46.22%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Alaunos (TCRT) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Alaunos Therapeutics (TCRT) is expected to provide an update on its pipeline candidates, Library TCR-T cell therapy and mbIL-15 TCR-T cell therapy, in its fourth-quarter earnings.
Assertio Holdings, Inc. (ASRT) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Assertio (ASRT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
The Cooper Companies (COO) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
The Cooper Companies (COO) delivered earnings and revenue surprises of 9.02% and 2.93%, respectively, for the quarter ended January 2023. Do the numbers hold clues to what lies ahead for the stock?
Oncternal Therapeutics (ONCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
by Zacks Equity Research
Oncternal Therapeutics (ONCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Earnings Season Could Be Great for Assertio (ASRT)
by Zacks Equity Research
Assertio (ASRT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Assertio (ASRT) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Assertio (ASRT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Assertio (ASRT) Soars 5.1%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Assertio (ASRT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Cronos Group (CRON) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cronos (CRON) delivered earnings and revenue surprises of -180% and 7.20%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
FibroGen (FGEN) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
FibroGen (FGEN) delivered earnings and revenue surprises of 26.32% and 43.89%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Assertio (ASRT) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Assertio (ASRT) closed at $5.12 in the latest trading session, marking a +1.19% move from the prior day.
Catalyst (CPRX) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Revenues of Catalyst Pharmaceuticals (CPRX) are expected to have been driven by the sales of its only marketed product, Firdapse, for treating LEMS, along with the drug's label expansion for the treatment of pediatric patients.
Assertio Holdings, Inc. (ASRT) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Zacks.com users have recently been watching Assertio (ASRT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Assertio (ASRT) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Assertio (ASRT) closed the most recent trading day at $5.10, moving +0.59% from the previous trading session.
Ardelyx Inc. (ARDX) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
Ardelyx (ARDX) is expected to report better-than-expected sales growth of its only marketed product, Ibsrela (tenapanor) and provide an update on the NDA resubmission timeline for Xphozah, tenapanor.
Assertio (ASRT) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On Assertio Holdings' (ASRT) Q4 earnings call, investors will focus on the sales performance of its marketed products.